5 Minute Read
Publish dateMar 7, 2023
Fenway Blends History and Innovation With AI-Powered Security Screening
WALTHAM, Mass. – (March 7, 2023) – Evolv Technology (NASDAQ: EVLV), the leader in AI-based weapons detection security screening, today announced its partnership with the Boston Red Sox and Fenway Park.
“America’s Most Beloved Ballpark” will feature Evolv’s state-of-the-art Evolv Express® screening solution beginning on Opening Day, March 30, when the Red Sox host the Baltimore Orioles. Fans will be able to seamlessly flow through security screening with less interruption for unnecessary alarms, reducing the backups and long lines that have historically developed at the entry gates. The partnership also joins two Boston-area organizations, as Waltham-based Evolv becomes a proud partner of its hometown team, the Boston Red Sox.
“The fan experience begins with creating a safe and secure environment at Fenway Park,” said Pete Nesbit, SVP Ballpark Operations, Boston Red Sox. “This partnership with Evolv enhances our overall security program with innovative weapons detection technology and the added benefit of a quicker, more efficient entry process.”
Evolv Express uses powerful sensor technology with artificial intelligence (AI) to provide safer, more accurate threat detection at unprecedented volume and speed. It allows security officials to tell the difference between threats and the everyday items people carry in their pockets and bags in a free flow manner. Fenway Park is one of ten Major League Baseball parks partnering with Evolv as the 2023 season begins.
“The Red Sox are always working to create one of the best fan experiences in all of sports,” said Peter George, CEO of Evolv Technology. “Fenway Park is already partnering with JCI to keep the historic ballpark more efficient, sustainable and ready for the future through their smart buildings platform. We are thrilled to add to a level of innovation in safety without sacrificing that experience that makes Fenway such a great place to visit.”
Between the Red Sox and Fenway Park and the New England Patriots and Gillette Stadium, Evolv screens fans in New England all year long. Both teams are part of an ever-growing roster of facilities in all sports across the country partnering with Evolv to provide a safer, faster and more fan-friendly entrance experience. Evolv’s technology is used at dozens of MLB, MLS and NFL stadiums from SoFi Stadium in Los Angeles to Mercedes-Benz Stadium in Atlanta to Nissan Stadium in Tennessee and is partnering with a growing roster of professional sports teams around the county.
About Evolv Technology
Evolv Technology (NASDAQ: EVLV) is transforming human security to make a safer, faster, and better experience for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces, using industry leading artificial intelligence (AI)-powered weapons detection and analytics. Its mission is to transform security to create a safer world to work,
learn, and play. Evolv has digitally transformed the gateways in places where people gather by enabling seamless integration combined with powerful analytics and insights. Evolv’s advanced systems have scanned more than 500 million people, second only to the Department of Homeland Security’s Transportation Security Administration (TSA) in the United States. Evolv has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT) as well as the Security Industry Association (SIA) New Products and Solutions (NPS) Award in the Law Enforcement/Public Safety/Guarding Systems category. Evolv Technology®, Evolv Express®, Evolv Insights®, and Evolv Cortex AI® are registered trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions. For more information, visit https://evolvtechnology.com.
Certain statements in this press release may constitute “forward-looking” statements and information, within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events or our Company’s performance and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the risk factors set forth in our Annual Report on Form 10-K for the year ended on December 31, 2021, that was filed with the SEC on March 28, 2022, as may be updated in other filings we make with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended on September 30, 2022 that was filed with the SEC on November 9, 2022. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
Alexandra Smith Ozerkis